Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021, with a specific reporting date of February 10, 2021. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Type | Instrument | Price (USD) | Volume | Date |
|---|---|---|---|---|
| Executive Supplemental Savings Plan | ADSs | $35.4600 | 1,188.063 | 2021-02-08 |
| 401(k) Plan | ADSs | $35.4600 | 212 | 2021-02-08 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of American Depositary Shares (ADSs) by an executive officer.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific transaction.
Key Facts for Investor Verification
- Executive Involved: Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: Acquisitions of GSK ADSs via the Executive Supplemental Savings Plan and the 401(k) Plan.
- Market Price: Transactions occurred at $35.46 per ADS on the New York Stock Exchange (XNYS).
- Total Volume: Approximately 1,400 ADSs acquired in total on February 8, 2021.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.